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a  b  s  t  r  a  c  t
Pulmonary  arterial  hypertension  (PAH)  has  been  described  to associate  with  hemolytic  anemia  in updated
clinical  classiﬁcation  of  pulmonary  hypertension.  A 56-year-old  woman,  diagnosed  with  warm  anti-
body  autoimmune  hemolytic  anemia  (AIHA),  was  treated  with  oral  corticosteroids  at the Department  of
Hematology,  Osaka  University  Hospital  for  30 years.  Her  AIHA  worsened  3 months  before  the  admission,
and  she  was  treated  with  rituximab  and  cyclosporine  in combination  with  prednisolone.  Soon  after  she
left  the  hospital,  she  developed  dyspnea  on  effort  and  leg  edema,  therefore  she was  re-admitted  to theutoimmune  hemolytic anemia
hosphodiesterase-5
itric oxide
Department  of  Cardiovascular  Medicine.  Echocardiogram  and  cardiac  catheterization  demonstrated  PAH
associated  with  AIHA.  She was  treated  with  three  types  of  vasodilatory  agents,  resulting  in an  improve-
ment  in pulmonary  arterial  pressure  and  pulmonary  vascular  resistance  after  6  weeks.  A  few weeks  after
she  left  the hospital,  her  hemolytic  anemia  became  in  remission  without  intensifying  AIHA therapy,  and
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Pulmonary arterial hypertension (PAH) has been described
o associate with hemolytic anemia, such as sickle cell disease,
halassemia, and paroxysmal nocturnal hemoglobinurea, in an
pdated clinical classiﬁcation of pulmonary hypertension [1]. The
revalence of PAH among patients with hemolytic anemia is esti-
ated as 10–40%, and there are several reports presenting poor
rognosis of PAH associated with chronic hemolytic anemia [2–4].
evertheless, PAH associated with autoimmune hemolytic anemia
AIHA) is uncommon and the precise etiology is still unclear [5].
ere, we report a case of PAH associated with AIHA and its suc-
essful treatment with vasodilatory agents.
ase report
A  56-year-old woman had been diagnosed with warm anti-
ody AIHA for 30 years and treated with oral corticosteroids at
he Department of Hematology, Osaka University Hospital. She
ever had a durable remission off therapy, and repeated exac-
rbations and remissions. As shown in Fig. 1, she had been
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 considered  when  the  ﬁrst-line  therapy  for  AIHA  failed  to  improve  PAH.
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treated with rituximab and cyclosporine in combination with pred-
nisolone for several years. During the past 30 years of observation,
her hemoglobin (Hb) concentration had never been maintained
over 12 g/dL even with chemotherapy and blood transfusion.
Her AIHA worsened in April 2010, e.g. Hb decreased to 6.8 g/dL
and lactate dehydrogenase (LDH) increased to1924 IU/L, therefore,
prednisolone was increased from 5 mg  to 10 mg daily and ritux-
imab (375 mg/m2, once a week) was  started. Her AIHA responded
well to these treatments and she was  discharged after 6 weeks of
hospitalization.
One month after she left the hospital, she felt exertional dyspnea
associated with leg edema and abdominal discomfort. She was then
admitted to the Department of Cardiology in July 2010. Physical
examination demonstrated that blood pressure was  110/62 mmHg,
pulse rate 78 beats/min, and arterial oxygen saturation was 99%
with 2 L/min nasal O2. Laboratory ﬁndings are summarized in
Table 1. The direct and indirect Coombs’ tests were 2+ and +,
respectively. Serological tests for connective tissue disease were
negative. Her chest radiography showed that cardiothoracic ratio
was 54% without pulmonary congestion and her electrocardiog-
raphy showed deep S wave in I, small Q in III, and inverted T
in III and V1–5, presenting right ventricular hypertrophy. Cardiac
echocardiography showed D-shaped left ventricular cavity with
ﬂuttering of interventricular septum in systole, the estimated right
ventricular systolic pressure (RVSP) was 63 mmHg  and the left
ventricular ejection fraction was 68%. Ultrasonography showed
no evidence of deep venous thrombosis in her legs. Right heart
vier Ltd. All rights reserved.
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Fig. 1. Clinical course (i). Clinical course and treatment history of autoimmune
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Fig. 2. Clinical course (ii). Sildenaﬁl, beraprost, and bosentan were started sequen-emolytic  anemia (AIHA). Figure presents changes in hemoglobin (Hb), lactate dehy-
rogenase (LDH), reticulocyte (Ret), and tricuspid regurgitant pressure gradient
TR-PG) for recent 4 years.
atheterization was performed on day 15, which revealed mean
ulmonary artery pressure (mPAP) 40 mmHg, pulmonary capillary
edge pressure (PCWP) 9 mmHg, and pulmonary vascular resis-
ance (PVR) 690 dyne s cm−5, and she was diagnosed as having PAH.
Initially, her pulmonary hypertension was thought to develop in
ssociation with pulmonary thromboembolism because of various
linical features and lung perfusion scintigraphy, which showed
egmental or sub-segmental defect. The contrast-enhanced
omputed tomography revealed no evidence of pulmonary throm-
oembolism. She was treated with diuretics and intravenous
nticoagulants, and her symptoms of heart failure improved, how-
ver, RVSP was unchanged. Subsequently, she was diagnosed
s having PAH presenting chronic thromboembolic pulmonary
ypertension-pattern of perfusion scintigraphy which was devel-
ped in association with AIHA worsening, and we started to treat
AH by using speciﬁc medications: sildenaﬁl, a phosphodiesterase-
 (PDE-5) inhibitor; beraprost, a prostacyclin analogue; and
osentan, an endothelin receptor antagonist. As shown in Fig. 2,
hese 3-types of vasodilatory agents were added sequentially. After
able 1
aboratory ﬁndings on admission.
WBC  6450/L C-reactive protein 0.15 mg/dL
RBC 230 × 104/L BNP 402.3 pg/mL
Hb 9.5 g/dL Direct Coombs’ test 2+
Hct 29.1% Indirect Coombs’ test 1+
MCV 126.3 Fl Antinuclear antibody (−)
MCHC 32.6% Vitamin B12 836 pg/mL
Reticulocytes 17.8% Folic acid 5.3 ng/mL
Platelet 36.2 × 104/L Haptoglobin <2 mg/dL
LDH 796 IU/L Blood gas analysis (2 L/min nasal O2)
Total bilirubin 2.8 mg/dL pH 7.450
Indirect bilirubin 1.8 mg/dL PaCO2 33.6 Torr
AST 49 IU/L PaO2 84 Torr
ALT 16 IU/L HCO3− 22.7 mmol/L
Na 146 mEq/L Base excess −0.6 mmol/L
K 4.0 mEq/L
Cl 111 mEq/L PT 42%
BUN 16 mg/dL APTT 33 s
Creatinine 0.81 mg/dL PT-INR 1.56
Uric acid 9.9 mg/dL D-dimer 0.7 pg/mL
Creatine kinase 30 IU/L
BC, white blood cells; RBC, red blood cells; Hb, hemoglobin; Hct, hemat-
crit;  MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin
oncentration;  LDH, lactate dehydrogenase; AST, aspartate-aminotransferase; ALT,
lanine-aminotransferase; BUN, blood urea nitrogen; BNP, brain natriuretic pep-
ide; PT, prothrombin time; APTT, activated partial thromboplastin time; PT-INR,
rothrombin time international normalized ratio.tially  from day 20 (2010/7/30). Sildenaﬁl was started from 20 mg  up to 60 mg,
beraprost  from 120 g to 360 g, and bosentan from 62.5 mg  to 125 mg.  Hb,
hemoglobin;  LDH, lactate dehydrogenase; TR-PG, tricuspid regurgitant pressure gra-
dient; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance.
a month of treatment, RVSP reduced to 45 mmHg  and the right heart
catheterization was repeated on day 50. The mPAP and the PVR
signiﬁcantly decreased to 32 mmHg  and 474 dyne s cm−5, respec-
tively, indicating that PAH was markedly improved.
She left the hospital on day 59, thereafter her Hb gradually
increased to 12 g/dL. Two months after the discharge, LDH and
reticulocytes simultaneously decreased to normal range, suggest-
ing that AIHA was  improved without intensifying AIHA therapy
(Fig. 2).
Discussion
PAH  is a syndrome of restricted blood ﬂow associated with
vasoconstriction, vascular remodeling, and thrombosis of small
pulmonary arteries. PAH includes idiopathic and heritable PAH
and associates with various conditions, such as connective tis-
sue disease, human immunodeﬁciency virus infection, portal
hypertension, and chronic hemolytic anemia [1]. To our knowl-
edge, there are few reports of PAH associated with AIHA. Zhang
et al. reported a case of PAH associated with AIHA as a ﬁrst case in
2007. They reported that AIHA was  successfully treated with corti-
costeroids, however PAH was unchanged [5]. AIHA is characterized
by an increased breakdown of red blood cells (RBC) due to auto-
antibodies with or without complement activation. Binding with
auto-antibody led to the sphering, increased osmotic fragility, and
impaired deformability of RBC [6,7]. Therefore, mechanically dam-
aged RBC may  increase pulmonary vascular resistance. A recent
report recognizes that hemolysis as an essential factor for the devel-
opment of PAH [8].
It  has been shown that cell-free Hb leads to nitric oxide deple-
tion due to nitric oxide scavenging, dysregulation of arginine
metabolism, and inhibition of endogenous nitric oxide synthesis.
Consequently, nitric oxide depletion induces platelet activation,
increases endothelin-1-mediated response, and enhances oxida-
tive stress. All those events in turn develop pulmonary vascular
remodeling, characterized by endothelial dysfunction, increased
vascular tone, inﬂammation, and hypercoagulability, which ulti-
mately result in pulmonary hypertension [9,10].
We  treated PAH by using three different types of vasodila-
tory agents, prostacyclin analogue, endothelin receptor antagonist,
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nd PDE-5 inhibitor, which improved mPAP, PVR, and RVSP sig-
iﬁcantly, and subsequently Hb increased to 12 g/dL without
ransfusion and LDH decreased to normal range. During the past
0 years of observation, her Hb concentration had never exceeded
2 g/dL without transfusion.
Recently, l-arginine supplementation or PDE-5 inhibition was
eported to improve hematologic and hemodynamic status in
atients with sickle cell disease [11]. They suggest that augmen-
ation of the cyclic nucleotide pathway by PDE-5 inhibition may
mprove hemodynamic and functional status in sickle cell disease.
lthough the precise mechanism for the improvement of anemia
n this case is unknown, reduction in PVR and mechanical dam-
ge of RBC using vasodilatory agents might additionally attribute
o prevent the hemolytic state.
In conclusion, we encountered a case of PAH associated with
IHA; her pulmonary hypertension was successfully treated with
asodilatory agents, and subsequently hemolytic anemia became
n remission without intensifying AIHA therapy. Although cor-
icosteroids are the ﬁrst-line treatment for AIHA, treatment for
ulmonary hypertension by speciﬁc agents should be considered
hen the ﬁrst-line therapy for AIHA failed to improve PAH.eferences
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